OSAKA, Japan & CAMBRIDGE, Mass. - Wednesday, 20. March 2024 AETOSWire
− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (ALL) in Combination with Chemotherapy
− First FDA Approval in Ph+ ALL Based on Novel Primary En…